Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lenvima
Pharma
Daiichi, Eisai, Granules—Fierce Pharma Asia
Merck and Daiichi's HER3 ADC delivered a positive phase 3 result. An FDA document details shortfalls at a Granules plant in India. Plus more.
Angus Liu
Sep 20, 2024 10:16am
Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype
Sep 14, 2024 10:30am
BMS, China reimbursement update, CAR-T hold—Fierce Pharma Asia
Dec 15, 2023 5:15am
Merck, Eisai combo flops again, this time in endometrial cancer
Dec 8, 2023 12:27pm
AZ-Daiichi, Padcev, AbbVie—Fierce Pharma Asia
Sep 29, 2023 10:45am
Merck and Eisai's cancer combo flops 2 more trials
Sep 22, 2023 9:51am
